Disclosed is an anti-tumor plant-medicament sustained-release tablet of elemene which comprises an elemene as an active component and is prepared by formulation of the elemene, a sustained-release agent, a bulking agent, a disintegrating agent, a binder and a lubricant, each component above-mentioned being in the following weight composition: the elemene 10%-15%, the sustained-release agent 3%-15%, the bulking agent 45%-70%, the disintegrating agent 3%-8%, the binder 1%-10%, and the lubricant 1%-8%. The sustained-release tablet of elemene provided in the invention has properties of expansion and adhesion, which in turn enables extending the retention time of the drug on upper and middle sections of the gastrointestinal tract. Therefore, the tablet may be taken b.i.d..times.3, in order to attain reduction in fluctuation of the plasma concentration, maintain effective plasma concentration for a longer period, and reduce the irritation on the gastrointestinal tract. The skeleton-type sustained- and controlled-release formulation has advantages of low cost, easy control, and easy industrialized production.

Xie; Tian

Fan; Haizhu

Zhan; Xiaori

Li; Chenglu

Zeng; Zhaowu

Anti-tumor plant-medicament sustained-release tablet of elemene

This invention provides an anti-cancer composition of high purity beta-elemene extracted from plant sources. This invention also provides for the use of the composition as well as a low cost method to prepare it by multiple passes through the precision distillation tower.

Yuan da International Group Limited

Beta-elemene, method to prepare the same and uses thereof

The present invention provides convergent processes for preparing (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, and (-)-beta-elemene fluoride and analogues thereof. Also provided are intermediates useful for preparing (-)-beta-elemene. The present invention further provides novel compositions based on analogues of (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and methods for the treatment of cancer, such as brain tumor, lung cancer, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric intestional cancer, and stomach cancer. The inventors propose a combination therapy using 1) one or more of the following anti-cancer agents: including, but not limited to, Cisplatin, 5-FU, Taxol, Taxol derivatives, and any anti-cancer agent, and 2) one or more of the following (-)-beta-elemene and its analogs, including (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride, and their analogs, and (-)-beta-elemene's intermediate in its chemical synthesis, for the treatment of cancer, especially for the treatment of brain tumor, lung cancer, ovarian cancer, bladder cancer, cervical cancer, colon cancer, breast cancer, and prostate cancer.

Huang; Lan

HYWE Pharmaceuticals, Inc.

Synthesis of (1)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates, and composition and uses thereof

elemene

kanker

neoplasms

elemene/kanker

Anti-tumor plant-medicament sustained-release tablet of elemene

Beta-elemene, method to prepare the same and uses thereof

Synthesis of (1)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates, and composition and uses thereof

De meest complete database met geneeskrachtige kruiden, ondersteund door de wetenschap